SC Licensing

SC Licensing sub-licenses the SCS’ proprietary portfolio of stem cell technologies to the biotechnology and pharmaceutical industries and research institutes. The technologies are valuable for efficient production, genetic engineering and selection of stem cells for use in drug discovery and basic research. SCS maintains a strong IP and technology position in the area of stem cell selection, gene expression, media formulations and specific stem cell types.

The Company’s current technology portfolio is composed of the following offering:

Stem Cell Selection Technology
Selection Technology allows the purification of specific stem cell types from a complex mixture of cells.

Internal Ribosome Entry Site (IRES)
IRES is used to monitor gene expression in living cells and gain an understanding about the function of individual genes, through the efficient insertion of a reporter or marker gene.

Various stem cell growth factors and media formulations
Proprietary technology and reagents needed for reproducible and robust stem cell growth developed through the SC Proven® Business Unit.

Neural Cell Technology (NS Technology)
NS Technology enables the derivation and growth of SCS’ patented NS cells. NS cells (mouse and human) are the first, mammalian tissue stem cells of any kind that can be stably grown outside the body as pure stem cells.

If you are interested in licensing any of these technologies from Stem Cell Sciences, please contact:

Alastair Riddell
Chief Executive Officer
alastair.riddell@stemcellsciences.com
+44 (0) 1223 499160